By Treven Pyles
Posted on July 10th, 2020
The incidence of esophageal cancer diagnosed in the United States is on the rise over the past two decades and so is the cost of its treatment. Patients with asbestos-exposure related esophageal cancer can always seek legal compensation that can help overcome financial hardships.
Esophageal cancer constitutes at least 1% of the cancers diagnosed among people living in the United States. The costs of esophageal cancer treatment vary widely and depend on the stage of the cancer and the type of treatment. The average monthly cost of treatment for esophageal cancer is the highest ($18,150) during the terminal phase lasting about 6 months and the lowest during the continuing phase ($2,984). The initial treatment costs average up to $7,731 and the staging costs can reach up to $8,953. A pattern of high staging and initial treatment costs followed by decreasing continuing phase costs and substantially increasing terminal phase costs can be found associated with the management of esophageal cancer.
The most common approaches of treatment for esophageal cancer include surgery, chemotherapy followed by surgery, chemoradiotherapy followed by surgery, and chemoradiotherapy. Esophageal cancer care costs also include hospitalization and supportive care costs. Here are the average costs of the different treatment approaches:
Depending on certain factors that are unique in each case, the cost of esophageal cancer care may vary. The factors that differ between individuals and influence the total cost incurred for esophageal cancer management include the age, staging of the cancer, treatment plan, cancer care provider/facility chosen for treatment, and health insurance coverage.
Generally, the costs of esophageal cancer treatment are the highest during the last months of life (terminal phase) as the patients will need high amounts of aggressive care including hospitalizations and intensive care unit (ICU) admissions. The terminal phase costs were $20,533 and $20,599 in Stage II and Stage III respectively.